October 10, 2015 10:06 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Spark Therapeutics, Inc. (NASDAQ: ONCE) announced today the presentation of additional data from the Phase 3 pivotal trial as well as continued durability data from an earlier Phase 1 study of SPK-RPE65, its lead product candidate for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). Principal Investigator Stephen R. Russell, MD, of the Stephen A. Wynn Institute for Vision Research at the University of Iowa, presented Phase 3 data highlighting the rate, breadth and magnitude of changes seen across the primary endpoint and first secondary endpoint following administration of SPK-RPE65. In addition, Dr. Russell presented data on the three-year durability of improvements in the same measures of functional vision and light sensitivity in a cohort of subjects from an earlier Phase 1 trial. Today's presentation builds on top-line results of a randomized controlled multi-center Phase 3 trial announced by Spark on October 5, which demonstrated a highly statistically
See full press release
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.